<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455999</url>
  </required_header>
  <id_info>
    <org_study_id>SYL1001_III</org_study_id>
    <nct_id>NCT02455999</nct_id>
  </id_info>
  <brief_title>Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sylentis, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sylentis, S.A.</source>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to compare the analgesic effect of two strengths of SYL1001
      eye drops versus placebo in patients with ocular pain associated with Dry Eye Syndrome.
      General and local tolerability are also evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from the baseline scoring of eye pain on the Visual Analogue Scale (VAS)</measure>
    <time_frame>10 consecutive days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from the baseline scoring of ocular discomfort in the Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>10 consecutive days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from the baseline scoring after fluorescein staining of the cornea</measure>
    <time_frame>10 consecutive days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of conjunctival hyperaemia</measure>
    <time_frame>10 consecutive days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in vital signs</measure>
    <time_frame>10 consecutive days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in standard laboratory parameters</measure>
    <time_frame>10 consecutive days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events (AEs) as a measure of SYL1001 safety</measure>
    <time_frame>20 consecutive days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in standard ocular parameters</measure>
    <time_frame>10 consecutive days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Ocular Pain</condition>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>SYL1001 eye drops dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYL1001 eye drops dose C administration via the ophthalmic route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYL1001 eye drops dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYL1001 eye drops dose D administration via the ophthalmic route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo eye drops administration via the ophthalmic route</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYL1001</intervention_name>
    <description>SYL1001 eye drops dose C administration for 10 consecutive days</description>
    <arm_group_label>SYL1001 eye drops dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYL1001</intervention_name>
    <description>SYL1001 eye drops dose D administration for 10 consecutive days</description>
    <arm_group_label>SYL1001 eye drops dose D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo eye drops administration for 10 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Give written informed consent to participate in the study, after having received all
             information relating to the design, aims and possible risks resulting therefrom.

          -  Common symptoms of persistent, daily, mild to moderate dry eye lasting more than three
             months: OSDI scale between 13-70 and VAS scale between 2 -7.

          -  Eye tests in both eyes: Corneal fluorescein staining (Oxford scale &gt; 0), Tear break-up
             time &lt; 10 seconds and Schirmer's test with anaesthesia &lt; 10 mm/5min.

        Exclusion criteria:

          -  Women who are pregnant or breastfeeding or who have a positive urine pregnancy test.
             Women who do not commit to use a medically acceptable method of contraception from the
             time of selection and throughout the study.

          -  Any current, relevant disease, including respiratory disease, cardiovascular disease,
             endocrine disease, neurological disease, haematological disease, kidney disease,
             oncological disease, liver disease, gastrointestinal dysfunction, hypertension or
             active acute infectious processes.

          -  Previous chronic or recurrent processes which, according to the investigator, could
             affect the development of the study.

          -  Concomitant use of other medications with analgesic activity by any route of
             administration at the time of entry into the study.

          -  Change in any concomitant eye and/or systemic medication of the patient one month
             before the study and during the study.

          -  Changes in the pre-established administration schedule of artificial tears during the
             15 days before the study and during the 10 days of the study.

          -  Initiation of treatment with cyclosporine or changes in the dosage or administration
             schedule of cyclosporine within the 6 months before inclusion in the study.

          -  History of hypersensitivity to drugs.

          -  Use of contact lenses during the treatment and previous 15 days.

          -  History of drug abuse or drug or alcohol dependence.

          -  Laboratory abnormalities which, in the investigator's opinion, are clinically
             significant.

          -  Previous refractive surgery.

          -  Having participated in another clinical trial within the 2 months prior to inclusion.

          -  Another eye disease that is significant in the investigator's opinion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Clinic Dr. Krista Turman</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

